Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tasimelteon in induced transient insomnia
NCT00291187Phase 3Completed
- Sponsor
- Vanda Pharmaceuticals Inc.
- Start
- Feb 2006
- Primary completion
- Aug 2006
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of tasimelteon in Insomnia (4 arms), sponsored by Vanda Pharmaceuticals Inc. Primary endpoint: Latency to Persistent Sleep. Started Feb 2006; status: completed.
02
Drugs
tasimelteon
03
Conditions
Insomnia
Beyond the preview
Go deeper on NCT00291187.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00291187.